168 related articles for article (PubMed ID: 25811345)
1. Implications of ubiquitin ligases in castration-resistant prostate cancer.
Qi J; Fan L; Hussain A
Curr Opin Oncol; 2015 May; 27(3):172-6. PubMed ID: 25811345
[TBL] [Abstract][Full Text] [Related]
2. PC-1 works in conjunction with E3 ligase CHIP to regulate androgen receptor stability and activity.
Wang J; Zhang H; Zhang X; Wang P; Wang H; Huang F; Zhou C; Zhou J; Li S
Oncotarget; 2016 Dec; 7(49):81377-81388. PubMed ID: 27835608
[TBL] [Abstract][Full Text] [Related]
3. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
4. LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer.
Zhang A; Zhao JC; Kim J; Fong KW; Yang YA; Chakravarti D; Mo YY; Yu J
Cell Rep; 2015 Oct; 13(1):209-221. PubMed ID: 26411689
[TBL] [Abstract][Full Text] [Related]
5. Targeting GRP78-dependent AR-V7 protein degradation overcomes castration-resistance in prostate cancer therapy.
Liao Y; Liu Y; Xia X; Shao Z; Huang C; He J; Jiang L; Tang D; Liu J; Huang H
Theranostics; 2020; 10(8):3366-3381. PubMed ID: 32206096
[No Abstract] [Full Text] [Related]
6. The E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity.
Qi J; Tripathi M; Mishra R; Sahgal N; Fazli L; Ettinger S; Placzek WJ; Claps G; Chung LW; Bowtell D; Gleave M; Bhowmick N; Ronai ZA
Cancer Cell; 2013 Mar; 23(3):332-46. PubMed ID: 23518348
[TBL] [Abstract][Full Text] [Related]
7. Lipocalin 2 over-expression facilitates progress of castration-resistant prostate cancer via improving androgen receptor transcriptional activity.
Ding G; Wang J; Feng C; Jiang H; Xu J; Ding Q
Oncotarget; 2016 Sep; 7(39):64309-64317. PubMed ID: 27602760
[TBL] [Abstract][Full Text] [Related]
8. Transcription of Nrdp1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer.
Savoy RM; Chen L; Siddiqui S; Melgoza FU; Durbin-Johnson B; Drake C; Jathal MK; Bose S; Steele TM; Mooso BA; D'Abronzo LS; Fry WH; Carraway KL; Mudryj M; Ghosh PM
Endocr Relat Cancer; 2015 Jun; 22(3):369-86. PubMed ID: 25759396
[TBL] [Abstract][Full Text] [Related]
9. Differential regulation of androgen receptor by PIM-1 kinases via phosphorylation-dependent recruitment of distinct ubiquitin E3 ligases.
Linn DE; Yang X; Xie Y; Alfano A; Deshmukh D; Wang X; Shimelis H; Chen H; Li W; Xu K; Chen M; Qiu Y
J Biol Chem; 2012 Jun; 287(27):22959-68. PubMed ID: 22584579
[TBL] [Abstract][Full Text] [Related]
10. Targeting Oct1 genomic function inhibits androgen receptor signaling and castration-resistant prostate cancer growth.
Obinata D; Takayama K; Fujiwara K; Suzuki T; Tsutsumi S; Fukuda N; Nagase H; Fujimura T; Urano T; Homma Y; Aburatani H; Takahashi S; Inoue S
Oncogene; 2016 Dec; 35(49):6350-6358. PubMed ID: 27270436
[TBL] [Abstract][Full Text] [Related]
11. p300-Mediated Acetylation of Histone Demethylase JMJD1A Prevents Its Degradation by Ubiquitin Ligase STUB1 and Enhances Its Activity in Prostate Cancer.
Xu S; Fan L; Jeon HY; Zhang F; Cui X; Mickle MB; Peng G; Hussain A; Fazli L; Gleave ME; Dong X; Qi J
Cancer Res; 2020 Aug; 80(15):3074-3087. PubMed ID: 32522824
[TBL] [Abstract][Full Text] [Related]
12. TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.
Singh R; Meng H; Shen T; Lumahan LEV; Nguyen S; Shen H; Dasgupta S; Qin L; Karri D; Zhu B; Yang F; Coarfa C; O'Malley BW; Yi P
Proc Natl Acad Sci U S A; 2023 May; 120(20):e2218229120. PubMed ID: 37155905
[TBL] [Abstract][Full Text] [Related]
13. Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
Liu C; Lou W; Yang JC; Liu L; Armstrong CM; Lombard AP; Zhao R; Noel ODV; Tepper CG; Chen HW; Dall'Era M; Evans CP; Gao AC
Nat Commun; 2018 Nov; 9(1):4700. PubMed ID: 30446660
[TBL] [Abstract][Full Text] [Related]
14. Commentary on "the E3 ubiquitin ligase Siah2 contributes to castration-resistant prostate cancer by regulation of androgen receptor transcriptional activity." Qi J, Tripathi M, Mishra R, Sahgal N, Fazli L, Ettinger S, Placzek WJ, Claps G, Chung LW, Bowtell D, Gleave M, Bhowmick N, Ronai ZA, Signal Transduction Program, Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA, USA.: Cancer Cell 2013;23(6):332-46.
Olumi AF
Urol Oncol; 2014 Feb; 32(2):210-1. PubMed ID: 24445292
[TBL] [Abstract][Full Text] [Related]
15. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
16. A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
Shen T; Dong B; Meng Y; Moore DD; Yang F
Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2205350119. PubMed ID: 36251994
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of androgen receptors by NaAsO
Kim Y; Park SE; Moon JW; Kim BM; Kim HG; Jeong IG; Yoo S; Ahn JB; You D; Pak JH; Kim S; Hwang JJ; Kim CS
Prostate; 2017 Jul; 77(10):1128-1136. PubMed ID: 28556958
[TBL] [Abstract][Full Text] [Related]
18. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
19. BCAR4 activates GLI2 signaling in prostate cancer to contribute to castration resistance.
Cai Z; Wu Y; Li Y; Ren J; Wang L
Aging (Albany NY); 2018 Dec; 10(12):3702-3712. PubMed ID: 30513511
[TBL] [Abstract][Full Text] [Related]
20. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
